Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck-Reference-Cited by-同舟云学术

Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck

Published:2022-10 Issue:5 Volume:49 Page:834-844
ISSN:0385-8146
Container-title:Auris Nasus Larynx
language:en
Short-container-title:Auris Nasus Larynx

Author:

Otsuki Shuya^ORCID,Hori Ryusuke^ORCID,Shinohara Shogo^ORCID,Kojima Tsuyoshi^ORCID,Tamaki Hisanobu,Asato Ryo,Kitamura Morimasa,Ichimaru Kazuyuki,Kitani Yoshiharu,Kumabe Yohei,Honda Keigo,Tsujimura Takashi,Harada Hiroyuki,Ushiro Koji,Omori Koichi^ORCID

Publisher

Elsevier BV

Subject

General Medicine,Otorhinolaryngology,Surgery

Reference26 articles.

1. Nivolumab for recurrent squamous-cell carcinoma of the head and neck;Ferris;N Engl J Med,2016

2. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141;Kiyota;Oral Oncol,2017

3. Two-year follow-up of a randomized phase III clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141);Yen;Head Neck,2020

4. Real-world outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic head and neck carcinoma;Hori;Cancers (Basel),2019

5. Investigation of the freely available easy-to-use software “EZR” for medical statistics;Kanda;Bone Marrow Transplant,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: a retrospective multi-center study by the Turkish Oncology Group (TOG);European Archives of Oto-Rhino-Laryngology;2024-05-25

2. Serum Albumin as an Independent Predictor of Long-Term Survival in Patients with Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Treated with Nivolumab;Journal of Clinical Medicine;2024-04-23

3. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada;Journal of Immunotherapy;2024-01-17

4. Chemotherapy following immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: clinical effectiveness and influence of inflammatory and nutritional factors;Discover Oncology;2023-08-29

5. Nivolumab;Reactions Weekly;2023-06-03